T. Rowe Price Investment Management
BBIO icon

T. Rowe Price Investment Management’s BridgeBio Pharma BBIO Stock Holding History

T. Rowe Price Investment Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,051,679
Closed -$54.6M – 907
2025
Q3 		$54.6M Buy
+1,051,679
New +$51.3M 0.03% 375
2024
Q3 		– Sell
-276,369
Closed -$7M – 626
2024
Q2 		$7M Sell
276,369
-1,168,748
-81% -$32M ﹤0.01% 558
2024
Q1 		$44.7M Buy
1,445,117
+9,837
+0.7% +$335K 0.03% 412
2023
Q4 		$57.9M Buy
1,435,280
+439,648
+44% +$13.2M 0.04% 370
2023
Q3 		$26.3M Buy
+995,632
New +$28.3M 0.02% 451

Other funds holding BBIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management's BBIO Position: Q4 2025 in Review

T. Rowe Price Investment Management sold out of BridgeBio Pharma (BBIO) in Q4 2025, closing a stake of 1,051,679 shares — an estimated $54.6M sold.

T. Rowe Price Investment Management first reported a position in BBIO in Q3 2023 and held it in 5 quarters. The position peaked at $57.9M in Q4 2023. 432 funds tracked by Wall St. Rank hold BBIO as of Q4 2025.

  • T. Rowe Price Investment Management reported no remaining BridgeBio Pharma position as of Q4 2025 after selling out during the quarter.
  • T. Rowe Price Investment Management sold 1,051,679 BridgeBio Pharma shares in Q4 2025, an estimated $54.6M.
  • T. Rowe Price Investment Management first reported a position in BridgeBio Pharma in Q3 2023 and held it in 5 quarters.
  • T. Rowe Price Investment Management's BridgeBio Pharma position peaked at $57.9M in Q4 2023.
  • 432 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2025.

Based on T. Rowe Price Investment Management's 13F filing for Q4 2025, filed 17 Feb 2026.